Trial
NCT04627675
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Providence Health & Services
Collaborators
OncoSec Medical Incorporated
Condition
SARS-CoV-2
Intervention
CORVax
Why stopped
Study was ended prematurely due to lack of efficacy. As per FDA guidance, our site continued to follow enrolled subjects through the 180 day safety visit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-26